Across TCGA pan-cancer cohorts, EFHC2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EFHC2 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher EFHC2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated EFHC2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SCLC show a favorable association.

CESC, UCEC, and HNSC are the cancer types where EFHC2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	OS	Median	All	0.411	0.880	<.001	48	view →
UCEC	DFS	Median	II,III,IV	1.000	0.427	.003	36	view →
HNSC	OS	Median	All	0.156	0.710	.002	30	view →
LUSC	DFS	Median	II,III,IV	0.220	0.721	<.001	20	view →
COAD	DFS	Median	II,III,IV	0.157	0.691	<.001	17	view →
SCLC	DFS	Median	All	1.000	0.272	.043	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: EFHC2 tumor-vs-normal RNA expression · all EFHC2 data types